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Abstract 
Background: Periprocedural myocardial injury (PMI) is a frequent complication of 
percutaneous coronary intervention (PCI) associated with poor prognosis. However, 
no effective method has been found to identify patients at risk of PMI before the 
procedure. MicroRNA-133a (miR-133a) has been reported as a novel biomarker in 
various cardiovascular diseases. Herein, it was sought to determine whether 
circulating miR-133a could predict PMI before the procedure. 
Methods: Eighty patients with negative preoperative values of cardiac troponin T 
(cTnT) receiving elective PCI for stable coronary artery disease (CAD) were 
recruited. Venous serum samples were collected on admission and within 16–24 hours 
post-PCI for miRNA measurements. PMI was defined as a cTnT value above the 99% 
upper reference limit (URL) after the procedure. The association between miR-133a 
and PMI was further assessed. 
Results: Periprocedural myocardial injury occurred in 48 patients. The circulating 
level of miR-133a was significantly higher in patients with PMI before and after the 
procedure (both p < 0.001). Receiver operating characteristic curve analysis of the 
preoperative miR-133a level revealed an area under the curve (AUC) of 0.891, with a 
sensitivity of 93.8% and a specificity of 71.9% to predict PMI. Additionally, a 
decrease was found in fibroblast growth factor receptor 1 (FGFR1) in parallel with an 
increase in miR-133a levels in patients with PMI. 
Conclusions: This study demonstrates for the first time that serum miR-133a can be 
used as a novel biomarker for early identification of stable CAD patients at risk of 
PMI undergoing elective PCI. The miR-133a-FGFR1 axis may be involved in the 
pathogenesis of PMI. 
Key words: periprocedural myocardial injury, percutaneous coronary 
intervention, microRNA-133a 
 
 
Introduction 
With emerging innovations in techniques and equipment, percutaneous coronary 
intervention (PCI) has been dramatically improved and is one of the most commonly 
used approaches for coronary revascularization. Complications of PCI, such as acute 
stent thrombosis, coronary perforation, stroke and death, are critical but rarely occur. 
In contrast, periprocedural myocardial injury (PMI) is a frequent complication 
associated with a poor prognosis, which can be detected in 5–40% of cases, even after 
an uneventful PCI procedure [1–3]. Some risk factors for PMI, such as older age and 
renal dysfunction, can be identified before the procedure [4, 5]. However, information 
about other crucial predictors, such as multivessel disease, stent length and stent 
number, are not available until the procedure is finished. No method has been found 
to effectively identify patients at a high risk of PMI preoperatively. 
MicroRNAs (miRNAs) represent a class of small noncoding RNAs that play an 
important role in posttranscriptional gene regulation by promoting mRNA degradation 
or direct translation inhibition. In the heart, miRNAs have been proposed as 
biomarkers in various cardiovascular diseases, such as heart failure [6], myocardial 
infarction [7] and arrhythmia [8]. miR-133a is a muscle-enriched miRNA that is 
critically involved in angiogenesis, apoptosis, cardiac fibrosis and hypertrophy [9]. In 
recent years, circulating miR-133a has been broadly reported as a biomarker of 
myocardial injury that correlates with troponin levels [9–12]. An elevated level of 
serum miR-133a in ST-elevation myocardial infarction (STEMI) patients is associated 
with more pronounced myocardial injury and a higher incidence of major adverse 
cardiovascular events (MACEs) [13]. However, whether the miR-133a signature is 
altered in stable CAD patients with PMI has not been thoroughly investigated. 
The present study was designed to ascertain the circulating level of miR-133a both 
before and after PCI. Furthermore, it was sought to determine whether PMI is 
associated with changes in miR-133a expression that could be identified 
preoperatively so that miR-133a may be used as a novel biomarker to predict PMI and 
rationalize early preventive strategies. 
 
Methods 
Ethics statement 
This study was approved by the Ethical Committee of Zhongshan Hospital, Fudan 
University (Approval NO: B2016-018, Date: 2016/02/29), and all patients gave their 
written, informed consent. The study was conducted in accordance with the tenets of 
the Declaration of Helsinki. 
 
Patient population 
Eighty stable CAD patients with negative preoperative cardiac troponin T (cTnT) 
levels scheduled for elective PCI were enrolled in Zhongshan Hospital, Fudan 
University. Patients with unstable angina pectoris, acute myocardial infarction, New 
York Heart Association class III–IV heart failure, moderate-to-severe valvular disease 
or bypass surgery history were excluded. Other exclusion criteria were active 
infection, respiratory failure, chronic kidney disease (eGFR < 60 mL/min/1.73 m2), 
liver dysfunction (liver enzyme >3× upper reference limit [URL] or bilirubin > 2× 
URL), malignancy and systemic connective tissue disease. Patients with a cTnT 
level > 0.03 ng/mL (99% URL) within 16–24 hours post-PCI were assigned to the 
PMI group. 
 
Serum collection and storage 
Venous blood samples were taken on admission before angiography and 16–24 
hours post-PCI. The serum was separated by centrifugation at 1000 g for 10 min at 
4°C. The supernatant was carefully transferred to RNase/DNase-free cryovials and 
stored at –80°C until assayed. 
 Measurement of serum miRNA 
Total RNA was isolated from 800 µL of serum and reverse transcribed according to 
the manufacturer’s instructions (GenePharma, Shanghai). Circulating levels of 
miRNAs were validated by quantitative real-time polymerase chain reaction (PCR) 
performed with specific TaqMan miRNA assays (Cat. # GMRS-001, GenePharma, 
Shanghai) using MX3000P (Stratagene, US). miR-16 was used as an internal standard 
to normalize the miRNA content, expressed as 2–CT(miR-16), and normalized to the mean 
value of the plate. The relative quantitation of miR-133a is expressed as 2–
CT(miRNA)/normalized miR-16 values, i.e., 2–△CT. The miRNA primers used in the assay 
are shown in Table 1. 
 
Serum fibroblast growth factor receptor 1 (FGFR1) detection 
The serum level of FGFR1 was determined in 100 µL of serum using a quantitative 
sandwich enzyme immunoassay (Cat. # PEL-FGFR1-γ, RayBiotech, Norcross, GA) in 
accordance with the manufacturer’s instructions. 
 
Statistical analyses 
Continuous variables are presented as mean ± standard deviation (SD) or as median 
with the interquartile range (IQR). Categorical data are expressed as counts and 
percentages. Differences between groups were assessed using the Fisher exact test or 
the chi‐square test for categorical variables. The Student t test and the Mann–Whitney 
U test were used to assess differences between groups in normally and non-normally 
distributed continuous variables, respectively. Univariable binary logistic regression 
analyses were performed to identify the risk factors for PMI. Correlation analyses 
were performed using the Spearman tests. A receiver operating characteristic (ROC) 
curve was established to predict patients with PMI. All probability values were two-
tailed, and p < 0.05 was considered significant. All analyses were performed with 
SPSS for Windows, release 25.0 (IBM SPSS, Inc., Chicago, IL, USA). Figures were 
plotted using GraphPad Prism, version 6.0 (GraphPad Software, San Diego, CA, 
USA). 
 
Results 
Baseline and procedural characteristics 
The baseline data for the recruited patients are summarized in Table 2. Briefly, most 
patients were men (58.8%), with a mean age of 63.1 years. The level of cTnT was 
elevated above the 99% upper reference limit (URL) in 48 patients after the 
procedure. Traditional risk factors for CAD, such as hypertension, diabetes, smoking 
history and dyslipidemia, were not significantly different in patients with or without 
PMI. Procedural features are presented in Table 3. Patients with PMI had a higher 
Syntax score (16.6 ± 9.4 vs. 10.4 ± 5.2, p = 0.002), indicating more complex coronary 
lesions. Compared with patients without PMI, more stents were implanted into 
patients with PMI, whose total stent length, as a result, was longer (66.6 ± 35.8 vs. 
35.5 ± 15.3 mm, p < 0.001). In addition, multivessel disease (defined as target vessels 
≥ 2) was more common in patients with PMI (6.2% vs. 43.8%, p < 0.001). 
Echocardiography revealed no difference in the ejection fraction (EF), left ventricular 
end-diastolic diameter (LVEDD), left atrial diameter or systolic pulmonary arterial 
pressure. 
 
Circulating miRNA profiles and cTnT values 
As shown in Figure 1, the baseline cTnT values were similar between groups. The 
median concentration of cTnT after PCI was 0.109 ng/mL (IQR 0.050–0.220) in the 
PMI group, corresponding to 0.016 ng/mL (IQR 0.011–0.021) in the non-PMI group. 
Of importance, the serum level of miR-133a was significantly increased in patients 
with PMI, even before the procedure (p < 0.001). In addition, the circulating signature 
of miR-133a did not change in either group after revascularization, that is, miR-133a 
was still substantially elevated in patients with PMI after PCI. The correlation 
between miR-133a and cTnT was positive based on the Spearman test (rs = 0.281, p < 
0.001), which, however, was not significantly high. 
 
Predictive value of circulating miR-133a for PMI 
Binary logistic regression analyses demonstrated that traditional risk factors for 
coronary heart disease, such as older age, hypertension, diabetes, and smoking history, 
did not predispose patients to PMI (Table 4). In contrast, stent length (≥ 30 mm), stent 
number as well as multivessel disease were associated with a higher risk of PMI, 
which, as mentioned above, could not be determined before the procedure. Of 
importance, ROC curve analyses implied that the preoperative miR-133a level could 
accurately predict PMI, with a sensitivity of 93.8%, a specificity of 71.9% and an area 
under the curve (AUC) of 0.891 (95% confidence interval [CI] 0.818–0.965) (Fig. 2). 
Furthermore, demonstrated herein, was that high circulating miR-133a (2–△CT > 
0.04427, the cut-off value derived from ROC analyses) increased the risk of PMI. 
After adjustment for stent length (≥ 30 mm), stent number and multivessel disease, it 
was found that elevated preoperative serum miR-133a was an independent risk factor 
of PMI (adjusted odds ratio = 34.20, 95% CI 6.34–184.39, data not shown). 
 
miR-133a and FGFR1 expression 
The FGFR1, a previously proven target of miR-133a, has been reported to be 
critically involved in glucose and lipid metabolism, oxidative stress and inflammatory 
responses, which seems to be associated with the pathogenesis of PMI. Therefore, we 
measured the serum level of FGFR1 and discovered that FGFR1 was significantly 
decreased in patients with PMI in parallel with the upregulation of miR-133a (Fig. 3), 
suggesting a potential role of the miR-133a-FGFR1 axis in the pathogenesis of PMI. 
 
Discussion 
In the present study, we evaluated the expression profile of circulating miR-133a in 
patients with and without PMI. Quantitative RT-PCR assessment implied that the 
serum level of miR-133a was significantly higher in patients with PMI both before 
and after the procedure. The present data demonstrated for first time that miR-133a 
was an independent risk factor of PMI and preoperative value of miR-133a could be 
used to accurately predict PMI in stable CAD patients undergoing elective PCI. As a 
target of miR-133a, the serum level of FGFR1 was correspondingly downregulated in 
patients with PMI, indicating that the miR-133a-FGFR1 axis may be involved in the 
pathological mechanism of PMI. 
No effective method has been validated to distinguish patients at an increased risk 
of PMI preoperatively. Some of the key factors that influence the incidence and 
magnitude of PMI could be discerned before the procedure, such as older age, pre-
existing renal impairment, and the presence of anemia [4, 14]. Nevertheless, 
angiographic and procedure-related factors, such as plaque burden, bifurcation 
lesions, stent number, stent length, the use of a rotablator or directional coronary 
atherectomy, cannot be ascertained until the procedure is finished [4]. Cardiac 
troponin can detect PMI only when risk factors take their toll. The delayed 
identification of PMI hinders the early adoption of a preventive strategy. 
It is acknowledged that PMI is closely related with two mechanisms: side branch 
loss and microcirculatory obstruction (structurally or functionally) [3]. Complex 
lesions and procedures were crucial determinants of PMI, which were associated with 
higher risk of side branch loss and microembolization from plaque debris. However, 
complex lesions or procedures are not bound to cause PMI, and uneventful PCI could 
lead to PMI. Since, presently it was believed complex lesions and procedures are 
components, but not the sole determinant of PMI. In this study, side branch 
obstruction was not found after double-checking each angiogram, which indicated the 
dominant role of coronary microcirculatory dysfunction. It was hypothesized herein, 
that disrupted microcirculation before PCI, disposed patients to a higher incidence of 
PMI and adverse cardiovascular events. 
Owing to their high stability in different biofluids, including serum, plasma and 
urine [15], the potential for microRNAs to serve as noninvasive biomarkers has drawn 
great interest. miR-133a is a muscle-enriched miRNA that has been reported to be 
increased in patients with myocardial infarction and is closely related to cardiac 
troponin [16]. Gacoń et al. [17] observed that miR-133a were significantly elevated in 
myocardial infraction patients with an occluded culprit coronary artery compared to 
those with patent culprit artery, while troponin levels did not differ between the two 
groups. This discordance between miRNA and cTn was also found in the present 
study, which implied higher sensitivity of miR-133a or a more complex role miR-
133a played in myocardial injury. Numerous studies confirmed that miR-133a was 
deeply involved in the pathological mechanisms of endothelial dysfunction [18], 
vascular smooth muscle cells proliferation and differentiation [19], as well as 
myocardial inflammation [20], which all could compromise the microvascular system. 
It was presently speculated that miR-133a may not only be a reflection of myocardial 
damage, but also a crucial risk factor to precipitate PMI. Notably, it was demonstrated 
that microvascular dysfunction reflected by index of microcirculatory resistance 
(IMR) was positively correlated with cTn values, and patients developed type 4a 
myocardial infarction had significantly higher IMR levels both at baseline and post-
PCI [21]. Besides, IMR were significantly increased after PCI in patients who 
developed type 4a myocardial infarction compared with those who did not. 
Consequently, it was believed that microcirculatory dysfunction did predispose 
patients to PMI, and PMI could invertedly deteriorate microcirculatory dysfunction. 
Unfortunately, IMR measurement couldn’t be accomplished in the present center to 
correlate IMR with miR-133a. Nevertheless, considering the current findings and 
previously published results, it was believed it would be convincing that a high level 
of serum miR-133a served as an index of microvascular dysfunction which disposed 
patients to high risk of PMI. The serum level of miR-133a was measured both before 
and after the procedure. Circulating miR-133a was significantly upregulated in PMI 
patients before PCI was performed. ROC analyses indicated that miR-133a could be 
used as a novel biomarker to distinguish patients at high risk of PMI, with an AUC of 
0.891. Using the cut-off value derived from ROC analyses,  a high level of 
preoperative circulating miR-133a was demonstrated and was an independent risk 
factor of PMI. Partially due to the relatively small sample number, the 95% 
confidence interval of odds ratio was wide and other baseline predictors, including 
age, diabetes, and prior PCI, did not increase the risk of PMI in this study. In addition, 
although the correlation of miR-133a and cTnT was positive, consistent with previous 
reports, the coefficient was not high. Different temporal releasing patterns may be one 
of the possible explanations for this inconsistency. Large-scale research is needed to 
validate the results and integrate multiple variables to generate a more precise model 
to predict PMI. 
This study provides the first documented insights into the miR-133a signature of 
PMI. The increased level of miR-133a before PCI implied a potential initiating role in 
the pathogenesis of PMI. FGFR1, as a target of miR-133a, is an important regulator in 
lipid and glucose metabolism [22], obesity, myocardial development, cardiac 
functional recovery [23], as well as vascular development and inflammation [24], 
which could possibly affect microcirculation. Hence, the serum level of FGFR1 was 
subsequently measured. In parallel with the increase in miR-133a, FGFR1 was 
significantly downregulated in patients with PMI both before and after the procedure. 
Therefore, a potential role of the miR-133a-FGFR1 axis in the pathogenesis of PMI 
can be speculated. The specific mechanism revealed herein was preliminary. More 
specific mechanisms of the miR-133a axis deserves further research. 
 
Limitations of the study 
There are some limitations acknowledged in the present study. First, the sample 
size was relatively small, and subjects were confined to stable CAD patients 
scheduled for elective PMI. Patients with active infection, respiratory failure, chronic 
kidney disease and so on were excluded in this study because these complications 
would influence the level of cTnT (in other words, PMI) independent of the 
interventional procedure. Large-scale research is required to confirm the results in 
broader populations. Second, only one serum sample was collected before and after 
PCI. More serum samples at different times are required to determine the time course 
of circulating miR-133a. Third, the exact source of the increased levels of miR-133a 
was not ascertained because miR-133a is also enriched in skeletal muscle. However, 
considering that creatine kinase values are not significantly different in patients with 
and without PMI, miR-133a is most likely released from the myocardium. Fourth, the 
pathogenesis of PMI is a multifactorial process, and the miR-133a-FGFR1 axis is 
unlikely to be the sole underlying mechanism. Finally, the clinical application of miR-
133a still relies on the development of robust and simple detection methods and 
validation of the cut-off values. 
 
Conclusions 
For the first time, this study demonstrated the overexpression of circulating miR-
133a in patients with PMI both before and after PCI. miR-133a was an independent 
risk factor of PMI. The preoperative miR-133a level can be used as a novel biomarker 
to accurately predict PMI in patients with stable CAD undergoing elective PCI. In 
addition, miR-133a-FGFR1 may be involved in the pathological mechanism of PMI.  
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 Table 1. MiRNA primer sequences. 
MiRNA Sequence 
 F primer AAGCACCTAGCAGCACGTAAATA 
hsa-mir-16 R primer TATGGTTTTGACGACTGTGTGAT 
 Size: 67bp  
 F primer GCCTTTGGTCCCCTTCAAC 
hsa-mir-133a R primer TATGCTTGTTCTCGTCTCTGTGTC 
 Size: 70bp  
 
 
Table 2. Baseline demographics and clinical characteristics. 
 Total (n = 
80) 
Non-PMI (n 
= 32) 
PMI (n = 48) P 
Age 63.1 ± 9.8 62.1 ± 10.6 64.5 ± 9.8 0.358 
Male 55 (68.8%) 22 (68.8%) 33 (68.8%) 1.000 
Hypertension 48 (60.0%) 20 (62.5%) 28 (58.3%) 0.709 
Diabetes 21 (26.3%) 6 (18.8%) 15 (31.3%) 0.213 
Smoking history 28 (35.0%) 11 (34.4%) 17 (35.4%) 0.924 
Prior PCI 18 (22.5%) 5 (15.6%) 1 3(27.1%) 0.229 
Laboratory and 
auxiliary 
examinations 
    
Creatinine 
[mg/dL] 
77.5 ± 16.6 77.7 ± 16.6 77.4 ± 16.8 0.951 
CK [U/L] 99.6 ± 53.6 114.5 ± 67.9 90.0 ± 39.8 0.228 
CK-MB [U/L] 16.6 ± 7.4 16.5 ± 10.4 16.7 ± 4.7 0.195 
hs-CRP [mg/L] 2.4 ± 4.3 1.5 ± 1.7 3.0 ± 5.4 0.502 
White blood cell 
count [×10^9/L] 
6.24 ± 1.63 5.96 ± 1.71 6.42 ± 1.57 0.230 
Platelet [×10^9/L] 208.2 ± 
55.6 
207.1 ± 41.3 209.0 ± 63.7 0.818 
Total cholesterol 
[mmol/L] 
3.72 ± 0.91 3.54 ± 0.70 3,83 ± 1.01 0.260 
LDL [mmol/L] 1.84 ± 0.79 1.72 ± 0.53 1.91 ± 0.92 0.584 
Triglycine 
[mmol/L] 
1.84 ± 1.15 2.02 ± 1.45 1.73 ± 0.91 0.617 
HDL [mmol/L] 1.11 ± 0.33 1.07 ± 0.31 1.14 ± 0.34 0.393 
Lp(a) [mmol/L] 287.0 ± 
339.6 
229.1 ± 238.1 324.7 ± 389.8 0.407 
HbA1c [%] 6.05 ± 0.80 6.08 ± 0.82 6.04 ± 0.79 0.823 
Echocardiograph
y 
    
Left atrium [mm] 38.5 ± 3.8 39.7 ± 4.3 38.2 ± 3.4 0.475 
LVEDD [mm] 46.1 ± 3.9 46.8 ± 3.9 45.7 ± 3.9 0.210 
SPAP [mmHg] 32.5 ± 7.2 33.0 ± 7.4 32.1 ± 7.1 0.184 
Ejection fraction 
[%] 
64.6 ± 8.1 65.6 ± 2.9 63.9 ± 10.1 0.365 
Data are shown as mean ± standard deviation or number (%). CK — creatine kinase; 
hs-CRP — high sensitive C-reactive protein; HDL — high density lipoprotein; LDL 
— low density lipoprotein; LVEDD — left ventricular end-diastolic diameter; Lp(a), 
lipoprotein (a); PMI — periprocedural myocardial injury; PCI — percutaneous 
coronary intervention; SPAP — systolic pulmonary arterial pressure 
 
 
Table 3. Angiographic and procedural features.  
Total (n= 80) Non-PMI (n 
= 32) 
PMI (n = 48) P  
Syntax score 14.1 ± 8.5 10.4 ± 5.2 16.6 ± 9.4 0.002 
CTO 8 (10.0%) 2 (6.3%) 6 (12.5%) 0.466 
Target vessel 
number 
    
1 57 (71.3%) 30 (93.8%) 27 (56.3%) < 0.001 
2 20 (25.0%) 2 (6.2%) 18 (37.4%) < 0.001 
3 3 (3.8%) – 3 (6.3%) < 0.001 
Multivessel 
disease* 
23 (28.8%) 2 (6.2%) 21 (43.7%) < 0.001 
Rotablation 2 (2.5%) 1 (3.1%) 1 (2.1%) 1 
PTCA without 
stenting 
1 (1.2%) 1 (3.1%) – < 0.001 
Stent number     
1 36 (45.0%) 21 (65.6%) 15 (31.3%) 0.001 
2 21 (26.2%) 10 (31.3%) 11 (22.9%) 0.407 
3 15 (18.8%) – 15 (31.3%) <0.001 
4 7 (8.8%) – 7 (14.6%) < 0.001 
Stent length 
[mm] 
54.2 ± 33.0 35.5 ± 15.3 66.6 ± 35.8 < 0.001 
Data are shown as mean ± standard deviation or number (%). *Means target vessel 
number ≥ 2; CTO — chronic total occlusion; PMI — periprocedural myocardial 
injury; PTCA — percutaneous transluminal coronary angioplasty 
 
 
Table 4. Risk factors of periprocedural myocardial injury.  
Odds ratio (95% CI) P 
Age ≥ 65 years 2.05 (0.82–5.08) 0.123 
Male 1.00 (0.38–2.63) 1 
Hypertension 0.84 (0.34–2.10) 0.709 
Diabetes 1.97 (0.67–5.78) 0.217 
Smoking history 1.05 (0.41–2.68) 0.924 
Prior PCI 2.01 (0.64–6.32) 0.234 
hs-CRP 1.13 (0.95–1.34) 0.167 
c-LDL 1.39 (0.73–2.65) 0.322 
Stent number 4.06 (1.99–8.31) < 0.001 
Stent length (≥ 30 
mm) 
3.00 (1.06–8.52) 0.039 
Multivessel disease* 11.7 (2.50–54.46) 0.002 
miR-133a (2–△CT > 
0.04427)$ 
38.33 (9.45–155.43) < 0.001 
*Means target vessel number ≥ 2. $ The cut-off value was derived from receiver 
operating characteristic analyses shown in Figure 2. Due to relatively small sample 
number, the 95% confidence international (CI) was wide. c-LDL — low-density 
lipoprotein cholesterol; hs-CRP — high sensitive C-reactive protein; PCI — 
percutaneous coronary intervention 
 
Figure 1. Periprocedural serum levels of miR-133a and cardiac troponin T (cTnT); A, 
B. Distribution of serum levels of miR-133a and cTnT in patients with or without 
periprocedural myocardial injury (PMI). Median and interquartile range of each 
category are shown in blue lines and numbers. Dotted line represents the 99% upper 
reference limit (URL) of cTnT; C, D. Comparison of miR-133a and cTnT levels. 
MiR-133a was substantially elevated in patients with PMI both before and after the 
procedure; ****p < 0.001. 
 
Figure 2. Receiver operating characteristic (ROC) curve for the prediction of 
periprocedural myocardial injury (PMI). The dotted diagonal line is the Null 
Hypothesis with area under the curve (AUC) = 0.500. MiR-133a(2–△CT > 0.04427) 
had a sensitivity of 93.8% and specificity of 71.9% to predict PMI with AUC = 0.891 
(95% confidence interval 0.818–0.965).  
 
Figure 3. Serum level of fibroblast growth factor receptor 1 (FGFR1). Circulating 
levels of FGFR1. FGFR1 was significantly down-regulated in patients with 
periprocedural myocardial injury both before and after the procedure; *p < 0.05; **p 
< 0.01. 



